HK Stock Market Move | TRANSCENTA-B(06628) is now trading up over 4%. ozekibart is expected to submit a marketing authorization application for US indication before the middle of next year.

14:03 31/10/2025

Chuangsheng Group-B (06628) rose nearly 10% at one point during the trading day, as of the time of this report, it is up 4.75% to HK$3.09, with a turnover of HK$4.06 million.

Transcenta-B (06628) rose nearly 10% intraday, and as of the time of writing, it had risen by 4.75% to HKD 3.09, with a trading volume of HKD 4.06 million. In terms of news, the Chuang Sheng Group announced that their partner, Inhibrx Biosciences, Inc. (INBX.US), recently released positive primary results from a registration clinical study evaluating the efficacy of the four-valent death receptor 5 (DR5) agonistic antibody ozekibart compared to placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Based on these results, Inhibrx plans to submit a market approval application for the chondrosarcoma indication of this product to US regulatory authorities by the end of June 2026. Chuang Sheng Group currently holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan.

During the third quarter, operating profit is expected to be approximately 1.35 billion to 1.5 billion yuan, a year-on-year increase of approximately 71.5% to 90.5%.

Hymson Laser Technology Group (688559.SH) plans to launch an employee shareholding plan in 2025.

Hymson Laser Technology Group (688559.SH) plans to launch a restricted stock incentive plan for 2,643,078 shares.

During the third quarter, operating profit is expected to be approximately 1.35 billion to 1.5 billion yuan, a year-on-year increase of approximately 71.5% to 90.5%.

Hymson Laser Technology Group (688559.SH) plans to launch an employee shareholding plan in 2025.

Hymson Laser Technology Group (688559.SH) plans to launch a restricted stock incentive plan for 2,643,078 shares.